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Abstract
Objective: Urinary cytokine/chemokine levels are elevated in adults with type 1 diabetes (T1D) exhibiting renal
hyperfiltration. Whether this observation extends to adolescents with T1D remains unknown. Our first objective was to
determine the relationship between hyperfiltration and urinary cytokines/chemokines in normotensive, normoalbuminuric
adolescents with T1D using GFRcystatin. Our second aim was to determine the relationship between urine and plasma levels
of inflammatory biomarkers, to clarify the origin of these factors.
Methods: Urine and serum cytokines/chemokines (Luminex platform) and GFRcystatin were measured in normofiltering
(n = 111, T1D-N, GFR,135 ml/min/1.73 m2) and hyperfiltering (n = 31, T1D-H, GFR$135 ml/min/1.73 m2) adolescents with
T1D (ages 10–16), and in age and sex matched healthy control subjects (HC, n = 59).
Results: We noted significant step-wise increases in urinary cytokine/chemokine excretion according to filtration status with
highest levels in T1D-H, with parallel trends in serum analyte concentrations. After adjusting for serum glucose at the time
of sampling, differences in urinary cytokine excretion were not statistically significant. Only serum IL-2 significantly differed
between HC and T1D (p = 0.0076).
Conclusions: Hyperfiltration is associated with increased urinary cytokine/chemokine excretion in T1D adolescents, and
parallel trends in serum cytokine concentration. The GFR-associated trends in cytokine excretion may be driven by the
effects of ambient hyperglycemia. The relationship between hyperfiltration, glycemia, and variations in serum and urine
cytokine expression and their impact on future renal and systemic vascular complications requires further study.
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Introduction
Diabetes mellitus is the most common cause of end-stage renal
failure requiring renal placement therapy in the developed world.
Unfortunately, despite the use of renin angiotensin aldosterone
system (RAAS) blockers and intensive glycemic control, a
significant proportion of patients continue to develop diabetic
nephropathy. Furthermore, in type 1 diabetes (T1D), RAAS
inhibition-based primary prevention of diabetic nephropathy,
defined by changes on renal biopsy, has been unsuccessful [1]. The
failure of current therapies may in part be due to a clinical inability
to distinguish high-risk patients from those who may never develop
complications. It is therefore critical to identify the role of
additional factors that contribute to the initiation and progression
of diabetic nephropathy to guide more targeted treatment
strategies.
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Hyperglycemia is necessary for the development of diabetic
nephropathy in experimental models and in humans [2,3,4]. In
young adult patients with T1D, acute clamped hyperglycemia
increases the urinary excretion of pro-inflammatory and pro-
fibrotic factors implicated in the pathogenesis of diabetic
nephropathy, including eotaxin, fibroblast growth factor-2, gran-
ulocyte-monocyte colony stimulating factor (GM-CSF), interferon-
a2, interleukin (IL)-12, IL-2, monocyte chemoattractant protein-3
(MCP-3), MCP-1, macrophage-derived chemokine (MDC), mac-
rophage inflammatory proteins-1a (MIP-1a), platelet derived
growth factor-BB (PDGF-AB/BB), tumour necrosis factor-b and
sCD40 Ligand (sCD40L) [5]. We have further shown that renal
hyperfiltration is associated with higher levels of urinary cytokines/
chemokines compared with T1D patients with normal GFR values
(T1D-N) and healthy controls (HC) [6]. Moreover, the increase in
urinary cytokine/chemokine excretion induced by hyperglycemia
is blunted by RAAS inhibition, and this effect is exaggerated in
patients with T1D and renal hyperfiltration (T1D-H) [7].
However, GFR in this previous work was measured directly by
inulin clearances under clamped glycemic conditions, and these
techniques can only be used in controlled research laboratory
setting. It is not known if renal hyperfiltration, defined with
clinically applicable cystatin C-based methods, is also associated
with increased urinary cytokine/chemokine excretion in an
ambulatory setting [8].
The identification of urinary biomarkers of preclinical kidney
disease that could be used clinically to distinguish adolescents with
T1D at increased risk of developing renal disease is an important
research goal for clinicians who take care of similar patients in the
pediatric setting and as these patients transition to adult care [9].
Accordingly, our aim was to determine the relationship between
GFR and urinary cytokines/chemokines in normotensive, nor-
moalbuminuric adolescents with T1D and normal renal function.
We hypothesized that in an adolescent cohort, urinary cytokines/
chemokines would be elevated in patients with T1D-H compared
to both T1D-N and a similar group of age and sex matched
healthy control participants.
Research Design and Methods
Study Population and Ethnics Statement
Patients were recruited from the longitudinal, observational,
non-interventional arm of the Adolescent Type 1 Diabetes Cardio-
Renal Intervention Trial (AdDIT), from clinical sites in the
Greater Toronto Area. In brief, the Non-Randomized Low-Risk
arm of AdDIT is a 4-year observational/natural history study,
following adolescents at low and middle risk of developing
microalbuminuria (EudraCT Number: 2007-001039-72). High-
risk adolescents are recruited into the AdDIT Interventional Study
(http://www.clinicaltrials.gov/ct2/show/NCT01581476), which
was designed to examine the effect of angiotensin converting
enzyme inhibitors and statins on renal, retinal and cardiovascular
endpoints. Our study did not include participants involved in the
intervention trial, however, as an ancillary component of Non-
Randomized Low-Risk arm of AdDIT we also included high-risk
subjects who chose not to enter the AdDIT Intervention Study. All
analyses in this manuscript were performed using biological
specimens and data collected from subjects enrolled in the
observational and ancillary arm of AdDIT, specifically baseline
data from the study obtained at Greater Toronto Area sites.
T1D patients were recruited from endocrinology clinics at The
Hospital for Sick Children, Credit Valley Hospital and Markham-
Stouffville in the Greater Toronto Area (Ontario, Canada), while
healthy controls were recruited through local advertisements. The
Hospital for Sick Children was the primary site of recruitment and
also coordinated recruitment at the secondary sites (REB#:
1000012240). The Hospital for Sick Children Research Ethics
Board, Credit Valley Hospital Ethics Forum and Markham-
Stouffville Research Ethics Board approved the protocol and the
consent procedure. In accordance to the Declaration of Helsinki,
written consent and informed consent was obtained from the legal
guardian/next of kin/caretakers of minors aged 15 and younger,
while the minors provided assent. All subjects, aged 16 and older
with capacity to understand the study information, gave complete
written and informed consent to participate in the study.
Normotensive, normoalbuminuric participants with T1D were
recruited. T1D patients were analyzed based on whether GFR was
in the normal range (n = 111, GFR 90–134 ml/min/1.73 m2) or
hyperfiltration range (n= 31, GFR$135 ml/min/1.73 m2) ac-
cording to Larsson method, as we have previously published
[8,10]. Fifty-nine healthy controls with normal renal function were
also included for comparison.
Inclusion criteria for T1D patients were: age 10–16, duration of
type 1 diabetes $1 year, no history of hypertension, proteinuria,
renal disease or macrovascular disease. Two sets of 3 early
morning urines were obtained and microalbuminuria was defined
as an ACR.3.5 mg/mmol/l in males and .4.0 mg/mmol/l in
females in 2 out of the 3 consecutive early morning urines [11]. In
addition to those delineated in the AdDIT observational protocol,
other exclusion criteria included chronic inflammatory disease,
anti-inflammatory or corticosteroid medicines or medications that
interfere with the renin angiotensin aldosterone system (RAAS)
[12].
Sample Collection and Analytical Methods
Participants were asked to provide a first morning urine sample.
This 50 ml mid-stream sterile urine specimen was used to measure
levels of cytokines/chemokines using an established Cytokine/
Chemokine Panel Luminex Assay urine creatinine concentration
[5,9]. Immediately after collection, urine was centrifuged at
1500 g for 15 minutes to remove cells, then separated into 1 ml
aliquots and frozen at 280uC. Urine was then thawed at 4uC one
day prior to use. Due to the urine specimen handling protocol
designed to avoid protein degradation, this analysis included spot
urines and not the timed collections. Furthermore, a priori we only
included selected analytes that either increase in response to
hyperglycemia or renal hyperfiltration in our previous work in
young adults [5,6]. Our analysis therefore included eotaxin, FGF-
2, GM-CSF, IFNa2, IL-2, IL-12, MCP-3, MCP-1, MDC, MIP-
1a, TNFb, sCD40L, PDGF-AB/BB. We limited our analysis to
these factors to maintain statistical power, to minimize false
positive results, and to further elucidate mechanisms that may link
high intraglomerular pressure with factors that promote initiation
of renal disease. The accuracy and precision of the urinary
cytokine/chemokine assay is available through the vendor at
http://www.millipore.com/userguides/tech1/proto_mpxhcyto-
60k. The detection limits of our assays have also been published
previously [9]. The investigator performing data analysis was
blinded to all study parameters.
Serum cystatin C was measured by a single operator using
thawed samples by an immunoassay (Dade Behring Diagnostics,
Newark, DE, USA) conducted on a BN Prospec System
nephelometer. The between-assay coefficient of variation in
samples from the lowest and highest quartiles of the cystatin C
distribution was 6.2 and 0.9%, respectively. Cystatin C based GFR
was derived using the body-surface area corrected Larsson
formula, as described previously, which has superior operating
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characterstics compared with creatinine-based measurements in
the hyperfiltration range using GFRINULIN [10,13].
Urinary albumin to creatinine ratio was determined from a spot
urine collection by immunoturbidimetry. Hemoglobin A1C
(HbA1c) was measured by high-performance liquid chromatogra-
phy [14].
Statistical analysis
All analyses in the manuscript were based on specimens and
data collected at the baseline visit. Descriptive statistics were used
to describe the sample. The baseline clinical and demographic
characteristics were compared using appropriate test statistics.
Between-group differences were determined by ANOVA, adjusted
for multiple comparisons using Bonferroni’s correction. The
statistical package SAS 9.3 (SAS Institute, Cary, NC, USA) was
used to analyze the data. Our sample size calculation was based on
differences in urinary MCP-1 excretion due to the consistent
relationship between this cytokine and renal disease. [5,6,15] Our
previous data have shown that the SD for MCP-1 is 17 units
[5,6,15]. To have an 80% power to detect a significant 25 unit
between-group difference in MCP-1, for a two- sided test with
p= 0.01, the sample size should be $16 per group. Participants
with diabetes were analyzed on the basis of filtration status
determined using cystatin C as described previously [8,10].
Filtration status was determined at the end of the study once
cystatin C and creatinine assays were complete for the entire
cohort. In the first analysis, between-group comparisons were
adjusted for age, gender, ACR and HbA1c. In the second analysis,
blood glucose at the time of the urine sample collection was
included rather than HbA1c, since our previous work has
demonstrated that acute, ambient glycemia increases urinary
cytokine/chemokine excretion [5,7]. Additional statistical correc-
tions for height and weight were not made because these
parameters are already accounted for in eGFR equations. Serum
levels of cytokines/chemokines were similarly analyzed using both




For baseline demographic and biochemical parameters, the
T1D-N had a higher proportion of males (56%) compared to HC
(44%) and T1D-H (40%), and significant differences in age, weight
and height were present (Table 1). The three groups had a
heterogeneous composition of ethnicities. As expected, SBP tended
to be higher in T1D groups compared to HC [16] and ACR
within the normal range was higher in the T1D groups vs. HC,
but the same in T1-N vs. T1D-H. For T1D-N and T1D-H,
HbA1c and diabetes duration values were similar.
The effect of renal filtration status on urinary cytokine/
chemokine excretion
After adjusting for baseline clinical characteristics including
HbA1c and ACR, the first pattern observed was a step-wise
increase from HC to T1D-N to T1D-H for urinary IL-12
(Figure 1, panel a, ANOVA p=0.0005). Pair-wise comparisons
were also significant except for HC vs. T1D-N (p= 0.0518). For
IFNa2 (Figure 1, panel b, ANOVA p=0.0019), pair-wise
differences between HC vs. T1D-H and T1D-N vs. T1D-H were
significant, while differences in HC vs. T1D-N were not. Finally,
levels of IL-2 (ANOVA p=0.0002), sCD40L (ANOVA p=0.001),
FGF-2 (ANOVA p=0.0038) (Figure 1, panels c–e), generally
increased from HC to T1D-N to T1D-H, but only pairwise
differences for HC vs. T1D-N and HC vs. T1D-H reached
significance. For TNF-b (ANOVA p=0.0097) and MIP-1a
(ANOVA p=0.0174) (Figure 1, panel f–g), only HC and T1D-
H group differences were significant. Similar trends for MDC,
MCP-3 and GM-CSF did not reach significance. When ethnicity
was added as a covariable to the regression model, between-group
differences in urinary cytokine/chemokine excretion persisted.
After adjusting for the same baseline clinical characteristics
including plasma glucose rather than HbA1c in a regression
analysis, between-group differences for IL-12 and IFNa2 were no
longer significant.
Correlation between urinary cytokines/chemokines and
renal function, adjusted for age, gender, ACR and
hemoglobin A1c
For HC, only PDGF-AB/BB (b=0.0433, p = 0.0019) correlated
with GFRcystatin C. In the T1D group, GFRcystatin C correlated with
MCP-1 (b=0.3189, p = 0.0162) and PDGF-AB/BB (b=0.0231,
p = 0.0331).
Serum levels of cytokines/chemokines in HC and T1D
Groups
For serum markers, between-group differences for IL-2 in HC
vs. T1D-N and T1D-H reached significance (Figure 2), and the
addition of ethnicity to the model had no effect. In the continuous
analysis comparing serum analyte levels with GFR in the HC
group, serum MIP-1a (b=20.2752, p = 0.0384), MDC (b=
212.702, p= 0.0061), IL-12 (b=22.1089, p = 0.0237) correlated
with GFRcystatin C. In the T1D cohort, correlations were also
observed between serum IL-12 (b=4.0269, p = 0.0029), IFNa2
(b= 15.8123, p = 0.0015), FGF-2 (b=2.1275, p = 0.0032), TNF-b
(b=21.7215, p = 0.0028), MDC (b=20.3889, p = 0.0018), GM-
CSF (b=1.1626, p = 0.0029), PDGF-AB/BB (b=20.0651,
p = 0.0232) and GFRcystatin C.
Correlation between urine and serum levels of cytokines/
chemokines in HC and T1D participants
In HC, none of the urine cytokines/chemokines correlated with
corresponding cytokines/chemokines in serum. In the T1D group,
correlations between urinary and plasma levels of eotaxin
(r = 0.20, p = 0.02), sCD40L (r = 0.22, p = 0.009) and GM-CSF
(r = 0.23, p= 0.0062) reached statistical significance.
Discussion
Albuminuria is an early clinical marker of diabetic nephropathy.
Unfortunately, albuminuria is limited as a predictive biomarker
because many patients exhibit stable levels of albuminuria and
never develop impaired renal function, and spontaneous regres-
sion of albuminuria is also common [17]. Furthermore, progres-
sive early GFR decline without albuminuria is common [18] and
may reflect underlying vascular disease and tubulointerstitial
inflammation rather than traditional diabetic glomerulosclerosis
[19,20]. The identification of sensitive and specific early biomark-
ers to predict the development of nephropathy prior to the onset of
albuminuria, such as urinary cytokines/chemokines, is therefore of
the utmost importance.
Urinary cytokine/chemokine excretion is associated with factors
that promote diabetic nephropathy, such as hyperglycemia, as well
as hyperfiltration, a surrogate marker for high intraglomerular
pressure leading to glomerulosclerosis [5,6]. Despite these
promising pathophysiological rationale for the use of cytokines/
chemokines as markers of early renal disease, the role of these
Urinary Proteomics, Hyperfiltration and Type 1 Diabetes
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factors as markers of diabetic nephropathy prior to the onset of
albuminuria remain unclear, especially in adolescents [21]. Our
aim was therefore to determine the relationship between GFR and
urinary cytokines/chemokines in a cohort of normotensive,
normoalbuminuric adolescents with T1D analyzed on the basis
of renal filtration status, since hyperfiltration may identify a group
of individuals who are at an increased risk of developing clinical
nephropathy in T1D and T2D [2,4].
Our first major finding was that renal hyperfiltration was
associated with higher levels of urinary cytokines/chemokines in
T1D adolescents prior to the development of microalbuminuria.
There were also parallel trends in serum cytokine concentrations.
This panel of biomarkers was selected due to associations between
these factors with 1) renal hyperfiltration and acute responses to
clamped hyperglycemia and 2) renal injury leading to diabetic
nephropathy, including chemotaxis, inflammation and fibrosis
[5,6] and 3) hyperglycemia-related increases in urinary excretion
of cytokine/chemokines, including IFN, PDGF, TNF and MCP-1
[22,23,24], leading to chronic kidney disease [25,26,27,28,29]. In
contrast with our previous work in adults using gold standard
inulin clearance techniques to measure GFR under clamped
euglycemic and hyperglycemic conditions, we used cystatin C-
based measurements, since this estimate of GFR can be used
clinically and has superior operating characteristics compared to
creatinine-based estimates within the hyperfiltration range when
compared to inulin clearances [8,10,30].
To account for the influence of ambient hyperglycemia at the
time of GFR measurement on urinary cytokines/chemokines, we
performed analyses with either HbA1c or plasma glucose as
covariables [5]. Ambient plasma glucose concentration was an
important determinant of urinary cytokine/chemokine excretion.
On regression analysis, adjustment for serum glucose at the time of
sampling mitigated the observed differences in cytokine excretion.
This observation supports the hypothesis that ambient hypergly-
cemia is an independent determinant of urinary inflammatory
biomarkers, and should be accounted for in future work. Chronic
glycemic control, reflected by HbA1C, did not have the same
confounding influence on cytokine excretion. This suggests that
perhaps transient glycemia is more important than chronic
glycemic status in determining acute variations in cytokine/
chemokine production.
Renal hyperfiltration has been attributed to hyperglycemia-
mediated activation of the RAAS causing efferent renal arteriolar
vasoconstriction, and also to diabetes related increases in proximal
tubular sodium-glucose cotransport, leading to altered tubuloglo-
merular feedback and afferent arteriolar vasodilatation [31,32].
Therefore, hyperglycemia may induce renal inflammation through
direct mitogenic, angiotensin II-dependent pathways, and may
also act indirectly through neurohormonal and tubular mecha-
nisms that raise intraglomerular pressure and wall tension, leading
to pro-inflammatory effects [33,34]. Regardless of the responsible
mechanism, hyperfiltration is associated with the initiation and
progression of nephropathy in T1D and T2D, and is present in
Table 1. Clinical Characteristics and Biochemistry in Healthy Controls and in Patients with Type 1 Diabetes Mellitus with







Male/female 26/33 63/48 9/22 0.017
Ethnicity – n (%)
White (Causcasian) 31 (52.5) 73 (65.8) 10 (32.3) 0.0005
Black (African, Caribbean) 3 (5.1) 7 (6.3) 4 (12.9) 0.395
South Asian 6 (10.2) 9 (8.1) 3 (9.7) 0.279
South East Asian 12 (20.3) 6 (5.4) 4 (12.9) 0.247
Aboriginal 0 0 0 -
Other 7 (11.9) 16 (14.1) 10 (32.2) 0.240
Age (years) 13.962.0 14.561.6 15.061.6 0.024
Diabetes duration (years) N/A 7.463.1 7.363.3 0.890
Weight (kg) 54.2613.0 62.2614.1 60.4616.13 0.017
Height (cm) 162612 165610 160610 0.0008
Systolic blood pressure (mmHg) 111610 116611 11467 0.683
Diastolic blood pressure (mmHg) 6867 6767 7067 0.359
Pulse (beats per minute) 4966.5 5269 4968 0.109
Biochemistry:
Blood glucose (mmol/L) 4.760.7 9.364.5 11.563.4 ,0.0001
HbA1c (%) 5.460.3 8.461.2 8.561.1 ,0.0001
HbA1c (mmol/mol) 3160.06 7560.15 7560.15
Urine albumin/creatinine ratio (mg/mmol) 0.6060.45 1.1462.46 1.1761.36 0.013
Serum LDL (mmol/L) 2.3860.76 2.2960.76 2.2460.51 0.773
Serum triglyceride (mmol/L) 0.9260.40 0.8460.40 0.8560.26 0.293
p-values provided for blood pressure are for z-scores; Blood glucose value obtained at the time of urine collection.
doi:10.1371/journal.pone.0111131.t001
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20–60% of young patients with T1D [2,4,35]. Mechanistically,
high intraglomerular pressure is associated with hyperfiltration
and increased wall tension in experimental diabetes, promoting
renal parenchymal inflammation [36,37]. To determine if a
similar relationship exists in humans, we previously compared
urinary cytokine/chemokine excretion in adult patients with T1D
with or without hyperfiltration defined by inulin-based clearances
under controlled laboratory conditions [5,6]. We demonstrated
that T1D-H exhibit higher urinary cytokines/chemokines levels
vs. T1D-N and HC [6]. In a separate study we demonstrated that
clamped hyperglycemia, a stimulus for hyperfiltration, also
increases urinary cytokine/chemokine excretion [5]. To determine
if hyperfiltration-related increases in urinary cytokines/chemo-
kines are reversible, we examined the effect of RAAS blockade on
these factors and demonstrated 1) a decline in many of these
mediators and 2) that these effects were exaggerated hyperfilterers
[7]. It was, however, unclear if these observations were applicable
outside of a controlled laboratory setting, or if our observations
would extend to an adolescent cohort. To our knowledge, the
present study is the first to examine the interaction between renal
Figure 1. Urinary Excretion of Cytokine/Chemokines in Adolescents with Type 1 Diabetes According to Hyperfiltration Status vs
Healthy Controls. Step-wise trends were observed for IL-12, IFNa2, IL-2, sCD40L, FGF-2, TNF-b, MIP-1a, MDC, MCP-3, GM-CSF, adjusted for age,
gender, ACR and HbA1c. P-values show pair-wise comparisons with Bonferroni correction. After adjusting for plasma glucose at the time of collection,
instead of HbA1c, pair-wise comparisons between normofilterers (T1D-N) and hyperfilterers (T1D-H) were no longer significant.
doi:10.1371/journal.pone.0111131.g001
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hyperfiltration, the earliest known hemodynamic abnormality
related to the development of diabetic nephropathy, and urinary
markers of inflammation in adolescents in a clinical setting. These
results therefore confirm our previous work in adults with T1D,
and suggest that inflammation associated with hyperfiltration
begins much earlier in the natural history of the disease, potentially
identifying an opportunity for future primary prevention strategies.
To determine whether the increase in urinary cytokines/
chemokines in T1D-H patients is due to high systemic levels
resulting in renal ‘‘overflow’’ or instead due to more local
production, we also measured serum levels of each factor. Our
second major finding was that in contrast with many between-
group differences for urinary factors, serum levels of IL-2 differed
between the three groups, with highest levels in T1D-H. Although
by no means definitive, this observation suggests an interaction
between systemic and renal levels of IL-2, possibly reflecting
systemic production and consequent renal clearance. Interestingly,
urinary levels of IL-12, IFNa2, FGF-2 and TNF-b tended to
increase from HC to T1D-N to T1D-H, and serum levels of these
factors correlated with GFR, again suggesting a relationship
between systemic and renal levels of these factors. Even in the
cases of MDC and GM-CSF where between-group differences for
Figure 2. Serum Cytokine/Chemokine Signature in Adolescents with Type 1 Diabetes Based on Hyperfiltration Status and Healthy
Controls. A parallel trend to urinary excretion of cytokine/chemokines was observed, although only IL-2 showed significance. P-values show pair-
wise comparisons with Bonferroni correction, adjusted for age, gender and HbA1c.
doi:10.1371/journal.pone.0111131.g002
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urinary levels were not significant, serum levels of these factors
tended to follow the same trend, with a positive correlation
between serum levels of GFR. We and others have previous
observed systemic hemodynamic abnormalities in T1D-H pa-
tients, including endothelial dysfunction and higher blood
pressure, suggesting that hyperfiltration reflects a generalized
abnormality of the endothelium and vasculature rather than an
isolated renal abnormality [16,38,39]. Therefore, our findings
suggest that at least for IL-2, IL-12, IFNa2, FGF-2 and TNF-b
higher urinary excretion rates in T1D-H may have been on the
basis of increased clearance from the systemic circulation rather
than renal production and subsequent urinary excretion.
In addition to increased risk of developing albuminuria and
GFR loss in clinical trials [2,4], T1D patients with hyperfiltration
including adolescents exhibit greater hemodynamic responses to
ACE inhibition, reflected by declines in GFR toward the normal
range [32]. We have also shown that T1D-H exhibit similar effects
when tubuloglomerular feedback is activated using the sodium
glucose cotransport inhibitor empagliflozin [40]. Finally, RAAS
blockade results in greater urinary cytokine/chemokine suppres-
sion in T1D-H versus T1D-N [7]. Hyperfiltration therefore
represents a distinct physiological state that identifies a subgroup
of patients who may be at an increased risk of diabetic
nephropathy, and who also exhibit greater hemodynamic and
molecular responses to potential renal protective agents. Regard-
less of the source of cytokines/chemokines in the present study
cohort, our results suggest that T1D-H patients generally exhibit
higher levels of factors that have been linked with renal and
cardiovascular injury. As such, patients with T1D-related hyper-
filtration may therefore represent a high-risk group that should be
targeted for earlier therapeutic interventions in future studies.
Our study has some important limitations. First, we were not
able to study this large cohort under clamped glycemic conditions.
We have demonstrated in previous work that strictly controlled
physiologic environment that transient hyperglycemia significantly
influences cytokine/chemokine levels. We therefore intentionally
sought to study this in a more realistic clinical setting, and
accounted for glycemia a priori with our analytic approach. A
second limitation was the use of GFR based on estimating
equations rather than direct GFR measures such as inulin.
Nevertheless, use of GFRcystatin C to define hyperfiltration has
provided important insights into how urinary cytokine/chemokine
excretion rates may be translated into the clinical setting in future
work [8]. Third, in this analysis, we hypothesized that between-
group differences in urinary cytokines/chemokines were primarily
on the basis of systemic overflow, and that increased renal
production was also possible. We recognize, however, that
children with T1D commonly exhibit evidence of proximal
tubular dysfunction [41,42] and we have recently reported that
proximal tubular function may be different in T1D-H vs. T1D-N
[31]. As such, future work should determine if physiological
differences in proximal tubule function, rather than activation of
inflammatory pathways, contribute to abnormalities in urinary
cytokine/chemokine handling, resulting in step-wise changes from
HC to T1D-N to T1D-H observed in this study. Finally, it is
important to recognize the cross-sectional nature of the data. As
such, we were unable to assess changes in urinary cytokine/
chemokine excretion over time, including the effect of intercurrent
illness or changes in glycemic control on these factors.
In conclusion, hyperfiltration in adolescents with T1D is
associated with higher levels of urinary cytokine/chemokine
excretion, an effect that is in part dependent on ambient blood
glucose levels. Future work is required to determine if high urinary
cytokine/chemokine excretion rates are associated with early renal
function decline or the onset of proteinuria. Future studies should
also determine if suppression of urinary cytokines/chemokines
with RAAS inhibition as observed in physiology studies can also be
achieved in a clinical setting and if declines in these factors
correlate with improved clinical outcomes [6].
Acknowledgments
Finally, the authors are grateful to the study participants whose time and
effort are critical to the success of our research program. The results
presented in this paper have not been published previously in whole or in
part. These data were presented in abstract form to the American Society
of Nephrology Meeting on November 9, 2013
Author Contributions
Conceived and designed the experiments: RLHH HNR JWS DD DBD
RM RND LM YE LD MO EBS FHM DZIC. Performed the experiments:
RLHH HNR JWS DD LM YE LD MO EBS FHM DZIC. Analyzed the
data: RLHH HNR JWS DD RM LM YE LD MO EBS FHM DZIC.
Contributed reagents/materials/analysis tools: RLHH HNR JWS DD
DBD RM RND LM YE LD MO EBS FHM DZIC. Wrote the paper:
RLHH HNR JWS DD DBD RM RND LM YE LD MO EBS FHM
DZIC.
References
1. Mauer M, Zinman B, Gardiner R, Suissa S, Sinaiko A, et al. (2009) Renal and
retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 361:
40–51.
2. Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, et al. (2009) Is
hyperfiltration associated with the future risk of developing diabetic nephrop-
athy? A meta-analysis. Diabetologia 52: 691–697.
3. Sasson AN, Cherney DZ (2012) Renal hyperfiltration related to diabetes mellitus
and obesity in human disease. World J Diabetes 3: 1–6.
4. Ruggenenti P, Porrini EL, Gaspari F, Motterlini N, Cannata A, et al. (2012)
Glomerular hyperfiltration and renal disease progression in type 2 diabetes.
Diabetes Care 35: 2061–2068.
5. Cherney DZ, Scholey JW, Sochett E, Bradley TJ, Reich HN (2011) The acute
effect of clamped hyperglycemia on the urinary excretion of inflammatory
cytokines/chemokines in uncomplicated type 1 diabetes: a pilot study. Diabetes
Care 34: 177–180.
6. Har R, Scholey JW, Daneman D, Mahmud FH, Dekker R, et al. (2013) The
effect of renal hyperfiltration on urinary inflammatory cytokines/chemokines in
patients with uncomplicated type 1 diabetes mellitus. Diabetologia 56: 1166–
1173.
7. Cherney DZI, Reich HN, Scholey JW, Daneman D, Mahmud F, et al. (2013)
The effect of aliskiren on urinary cytokine/chemokine responses to hypergly-
cemia in type 1 diabetes mellitus. Diabetologia epub July 28.
8. Cherney DZ, Sochett EB, Dekker MG, Perkins BA (2010) Ability of cystatin C to
detect acute changes in glomerular filtration rate provoked by hyperglycaemia in
uncomplicated Type 1 diabetes. Diabet Med 27: 1358–1365.
9. Cherney DZI, Scholey JW, Daneman D, Dunger DB, Dalton N, et al. (2012)
Urinary markers of renal inflammation in subjects with type 1 diabetes and
normoalbuminuria. Diabetic Medicine March 14.
10. Perkins BA, Sochett EB, Cherney DZ (2012) Ability of Cystatin C to detect
changes in glomerular filtration rate after ACE inhibition in patients with
uncomplicated type 1 diabetes. Clin Exp Hypertens 34: 606–611.
11. Group TDCaCTEoDIaCR (2000) Retinopathy and Nephropathy in Patients
with Type 1 Diabetes Four Years after a Trial of Intensive Therapy. New
England Journal of Medicine 342: 381–389.
12. AdDIT Study Group (2009) Adolescent type 1 Diabetes Cardio-renal
Intervention Trial (AdDIT). BMC Pediatr 9: 79.
13. Bacchetta J, Cochat P, Rognant N, Ranchin B, Hadj-Aissa A, et al. (2011)
Which creatinine and cystatin C equations can be reliably used in children?
Clin J Am Soc Nephrol 6: 552–560.
14. Cherney DZ, Miller JA, Scholey JW, Nasrallah R, Hebert RL, et al. (2010)
Renal hyperfiltration is a determinant of endothelial function responses to
cyclooxygenase 2 inhibition in type 1 diabetes. Diabetes Care 33: 1344–1346.
15. Cherney DZ, Scholey JW, Daneman D, Dunger DB, Dalton RN, et al. (2012)
Urinary markers of renal inflammation in adolescents with Type 1 diabetes
mellitus and normoalbuminuria. Diabet Med 29: 1297–1302.
Urinary Proteomics, Hyperfiltration and Type 1 Diabetes
PLOS ONE | www.plosone.org 7 November 2014 | Volume 9 | Issue 11 | e111131
16. Yang GK, Maahs DM, Perkins B, Cherney DZI (2013) Renal Hyperfiltration
and Systemic Blood Pressure in Patients with Uncomplicated Type 1 Diabetes
Mellitus. PLoS One 8: e68908.
17. Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, et al. (2007)
Microalbuminuria and the risk for early progressive renal function decline in
type 1 diabetes. J Am Soc Nephrol 18: 1353–1361.
18. Dwyer JP, Parving HH, Hunsicker LG, Ravid M, Remuzzi G, et al. (2012)
Renal Dysfunction in the Presence of Normoalbuminuria in Type 2 Diabetes:
Results from the DEMAND Study. Cardiorenal Med 2: 1–10.
19. Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, et al.
(2009) Urinary peptidome may predict renal function decline in type 1 diabetes
and microalbuminuria. J Am Soc Nephrol 20: 2065–2074.
20. Perkins BA, Krolewski AS (2009) Early nephropathy in type 1 diabetes: the
importance of early renal function decline. Curr Opin Nephrol Hypertens 18:
233–240.
21. Wolkow PP, Niewczas MA, Perkins B, Ficociello LH, Lipinski B, et al. (2008)
Association of urinary inflammatory markers and renal decline in microalbu-
minuric type 1 diabetics. J Am Soc Nephrol 19: 789–797.
22. Morii T, Fujita H, Narita T, Shimotomai T, Fujishima H, et al. (2003)
Association of monocyte chemoattractant protein-1 with renal tubular damage
in diabetic nephropathy. J Diabetes Complications 17: 11–15.
23. Banba N, Nakamura T, Matsumura M, Kuroda H, Hattori Y, et al. (2000)
Possible relationship of monocyte chemoattractant protein-1 with diabetic
nephropathy. Kidney Int 58: 684–690.
24. Wada T, Furuichi K, Sakai N, Iwata Y, Yoshimoto K, et al. (2000) Up-
regulation of monocyte chemoattractant protein-1 in tubulointerstitial lesions of
human diabetic nephropathy. Kidney Int 58: 1492–1499.
25. Rao GN, Corson MA, Berk BC (1991) Uric acid stimulates vascular smooth
muscle cell proliferation by increasing platelet-derived growth factor A-chain
expression. J Biol Chem 266: 8604–8608.
26. Sanchez-Lozada LG, Nakagawa T, Kang DH, Feig DI, Franco M, et al. (2006)
Hormonal and cytokine effects of uric acid. Curr Opin Nephrol Hypertens 15:
30–33.
27. Litwin M, Michalkiewicz J, Niemirska A, Gackowska L, Kubiszewska I, et al.
(2010) Inflammatory activation in children with primary hypertension. Pediatr
Nephrol 25: 1711–1718.
28. Tominaga M, Uno K, Yagi K, Fukui M, Hasegawa G, et al. (2010) Association
between capacity of interferon-alpha production and metabolic parameters.
J Interferon Cytokine Res 30: 451–454.
29. Mene P, Punzo G (2008) Uric acid: bystander or culprit in hypertension and
progressive renal disease? J Hypertens 26: 2085–2092.
30. Odutayo A, Cherney D (2012) Cystatin C and acute changes in glomerular
filtration rate. Clin Nephrol 78: 64–75.
31. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, et al. (2014) The
Renal Hemodynamic Effect of SGLT2 Inhibition in Patients with Type 1
Diabetes. Circulation 129: 587–597.
32. Sochett EB, Cherney DZ, Curtis JR, Dekker MG, Scholey JW, et al. (2006)
Impact of renin angiotensin system modulation on the hyperfiltration state in
type 1 diabetes. J Am Soc Nephrol 17: 1703–1709.
33. Cherney DZ, Scholey JW, Miller JA (2008) Insights into the regulation of renal
hemodynamic function in diabetic mellitus. Curr Diabetes Rev 4: 280–290.
34. Mezzano S, Droguett A, Burgos ME, Ardiles LG, Flores CA, et al. (2003) Renin-
angiotensin system activation and interstitial inflammation in human diabetic
nephropathy. Kidney Int Suppl: S64–70.
35. Moriya T, Tsuchiya A, Okizaki S, Hayashi A, Tanaka K, et al. (2012)
Glomerular hyperfiltration and increased glomerular filtration surface are
associated with renal function decline in normo- and microalbuminuric type 2
diabetes. Kidney Int 81: 486–493.
36. Riser BL, Cortes P, Heilig C, Grondin J, Ladson-Wofford S, et al. (1996) Cyclic
stretching force selectively up-regulates transforming growth factor-beta isoforms
in cultured rat mesangial cells. Am J Pathol 148: 1915–1923.
37. Riser BL, Cortes P, Zhao X, Bernstein J, Dumler F, et al. (1992) Intraglomerular
pressure and mesangial stretching stimulate extracellular matrix formation in the
rat. J Clin Invest 90: 1932–1943.
38. Pecis M, Azevedo MJ, Gross JL (1997) Glomerular hyperfiltration is associated
with blood pressure abnormalities in normotensive normoalbuminuric IDDM
patients. Diabetes Care 20: 1329–1333.
39. Cherney DZ, Reich HN, Jiang S, Har R, Nasrallah R, et al. (2012)
Hyperfiltration and the effect of nitric oxide inhibition on renal and endothelial
function in humans with uncomplicated type 1 diabetes mellitus. Am J Physiol
Regul Integr Comp Physiol 303: R710–718.
40. Cherney DZI, Perkins BA, Soleymanlou N, Maione M, Lai V, et al. (2013) The
Renal Hemodynamic Effect of SGLT2 Inhibition in Patients with Type 1
Diabetes. Circulation, in press.
41. Schultz CJ, Dalton RN, Neil HA, Konopelska-Bahu T, Dunger DB (2001)
Markers of renal tubular dysfunction measured annually do not predict risk of
microalbuminuria in the first few years after diagnosis of Type I diabetes.
Diabetologia 44: 224–229.
42. Hourd P, Edge JA, Dunger DB, Dalton N, Edwards R (1991) Urinary growth
hormone excretion during puberty in type 1 (insulin-dependent) diabetes
mellitus. Diabet Med 8: 237–242.
Urinary Proteomics, Hyperfiltration and Type 1 Diabetes
PLOS ONE | www.plosone.org 8 November 2014 | Volume 9 | Issue 11 | e111131
